NervGen Pharma Extends the Expiry Date of Certain Stock Options
NervGen Pharma Extends the Expiry Date of Certain Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Options") granted to a consultant of the Company on April 23, 2021 and July 16, 2021, such that the terms of the Options shall be extended from three (3) years to five (5) years following the original grant dates, respectively. All other terms of the Options, including the exercise price, remain the same.
温哥华，不列颠哥伦比亚省-(Newsfile Corp.-2023年6月2日)-NervGen制药公司(TSXV：NGEN)(OTCQX：NGENF)(“NervGen”或“公司”)，一家致力于开发治疗神经系统损伤的创新解决方案的临床期生物技术公司，宣布将某些股票期权的到期日延长两年。选项“)于二零二一年四月二十三日及二零二一年七月十六日授予本公司顾问，使购股权条款分别由原来授出日期起计三(3)年延展至五(5)年。所有其他购股权条款，包括行使价，均维持不变。
About NervGen
关于NervGen
NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The Company's initial target indications are spinal cord injury, Alzheimer's disease, and multiple sclerosis. For more information, go to .
NervGen是一家临床阶段的生物技术公司，致力于开发创新的治疗方法，使神经系统在受损后能够自我修复，无论是由于受伤还是疾病。该公司最初的目标适应症是脊髓损伤、阿尔茨海默病和多发性硬化症。有关更多信息，请访问。
For further information, please contact:
如需更多信息，请联系：
Bill Adams, Chief Financial Officer
badams@nervgen.com
比尔·亚当斯，首席财务官
邮箱：baadams@nergen.com
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Huitt Tracey，企业传播部
邮箱：htrey@nerggen.com
604.537.2094
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所创业板交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问